Cancer Drug Prices in India: UPSC 2027 Analysis
Reducing the maximum retail price (MRP) of cancer medicines can help patients, but it does not automatically make cancer treatment affordable. Patients may still face substantial expenses for diagnostics, hospital visits, multiple medicines, travel and lost wages. The 6 November 2026 current-affairs discussion highlights the distinction between a medicine's labelled price and the total cost of effective cancer care. It also examines the role of India's National Pharmaceutical Pricing Authority (NPPA), drug-price regulation, insurance coverage, medicine availability and quality-assured generic competition. This article analyses why price ceilings alone cannot guarantee equitable access to cancer treatment and explains how better procurement, stronger public oncology services, financial protection and patient-centred affordability indicators can improve outcomes. Designed for UPSC Prelims and Mains 2027, the article includes GS Paper II, III and IV analysis, practice MCQs, Mains questions, an answer-writing framework and FAQs.